NOEMI
MANCEÑIDO MARCOS
PROFESOR DOCTOR
![Foto de NOEMI](/img/nophoto.png)
![Foto de Hospital de Fuenlabrada](/img/noimage_org.png)
Hospital de Fuenlabrada
Fuenlabrada, EspañaPublicacións en colaboración con investigadores/as de Hospital de Fuenlabrada (17)
2024
-
Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry
Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264
-
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588
2023
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247
2022
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2021
-
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851
-
Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42
2019
-
Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
Current Medical Research and Opinion, Vol. 35, Núm. 7, pp. 1297-1304
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
2015
-
Effectiveness of adalimumab in perianal fistulas in Crohn's disease patients naive to Anti-TNF therapy
Journal of Clinical Gastroenterology, Vol. 49, Núm. 1, pp. 34-40
-
Incidence, management, and course of cancer in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 9, Núm. 4, pp. 326-333
2012
-
Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases
Journal of Crohn's and Colitis, Vol. 6, Núm. 5, pp. 518-523
2011
-
Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients
Alimentary Pharmacology and Therapeutics, Vol. 34, Núm. 5, pp. 544-554
2010
-
Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: The RECLICU Study
Journal of Crohn's and Colitis, Vol. 4, Núm. 6, pp. 629-636
2009
-
Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement
Inflammatory Bowel Diseases, Vol. 15, Núm. 10, pp. 1485-1491